141 related articles for article (PubMed ID: 24274866)
1. The role of medications for the management of patients with NAFLD.
Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Ratziu V; Caldwell S; Neuschwander-Tetri BA
Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
[TBL] [Abstract][Full Text] [Related]
4. Therapy for nonalcoholic fatty liver disease.
Moseley RH
J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
[No Abstract] [Full Text] [Related]
5. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.
Marchesini G; Moscatiello S; Agostini F; Villanova N; Festi D
Expert Opin Emerg Drugs; 2011 Mar; 16(1):121-36. PubMed ID: 21352073
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease and lipids.
Wierzbicki AS; Oben J
Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
[TBL] [Abstract][Full Text] [Related]
7. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic management of nonalcoholic fatty liver disease.
Harrison SA; Neuschwander-Tetri BA
Clin Liver Dis; 2004 Aug; 8(3):715-28, xii. PubMed ID: 15331071
[TBL] [Abstract][Full Text] [Related]
11. Review article: Drug therapy for non-alcoholic fatty liver disease.
Comar KM; Sterling RK
Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
[TBL] [Abstract][Full Text] [Related]
12. Expert opinion on current therapies for nonalcoholic fatty liver disease.
Della Corte C; Alisi A; Iorio R; Alterio A; Nobili V
Expert Opin Pharmacother; 2011 Aug; 12(12):1901-11. PubMed ID: 21639814
[TBL] [Abstract][Full Text] [Related]
13. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
[TBL] [Abstract][Full Text] [Related]
14. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
Chavez-Tapia NC; Barrientos-Gutierrez T; Tellez-Avila FI; Sanchez-Avila F; Montano-Reyes MA; Uribe M
World J Gastroenterol; 2006 Dec; 12(48):7826-31. PubMed ID: 17203528
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic therapy for nonalcoholic fatty liver disease in adults.
Malinowski SS; Byrd JS; Bell AM; Wofford MR; Riche DM
Pharmacotherapy; 2013 Feb; 33(2):223-42. PubMed ID: 23359475
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease: current and potential therapies.
Ibrahim MA; Kelleni M; Geddawy A
Life Sci; 2013 Feb; 92(2):114-8. PubMed ID: 23159641
[TBL] [Abstract][Full Text] [Related]
17. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
18. Use of insulin sensitizers in NASH.
Khashab M; Chalasani N
Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
[TBL] [Abstract][Full Text] [Related]
19. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for non-alcoholic steatohepatitis.
Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
